Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Extracellular vesicles for macrophage reprogramming: an emerging paradigm in immunomodulatory therapeutics

Jo HY., Kim MK., Kim KT., Choi C., Rhee WJ.

Narrative Review on Chronic Inflammation, Immune Modulation, published in J Biol Eng (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Biol Eng (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41430279
PMCID
PMC12837104
DOI
10.1186/s13036-025-00594-w
Citations
5

Abstract (original English)

Macrophages are pivotal regulators of immunity, and due to their ability to differentiate into either pro-inflammatory (M1) or anti-inflammatory (M2) phenotypes with remarkable plasticity, they can be used as strategies for treating diseases ranging from cancer to chronic inflammatory conditions. However, despite extensive research, the mechanisms driving macrophage polarization and the role of extracellular vesicles (EVs) in regulating these processes remain not fully understood. In particular, the specific signaling pathways and clinical applications of EV-mediated macrophage reprogramming are still under active investigation. Many recent studies have shown that EVs alter the immune environment by reprogramming macrophages to transition between M1 and M2 polarized states, thereby exhibiting therapeutic activity in a variety of diseases, including cancer. In addition, EV engineering aimed at improving macrophage reprogramming capabilities has been shown to enhance therapeutic efficacy, providing unprecedented opportunities to overcome previously untreatable diseases. This review addresses ongoing challenges by examining the latest findings on EV-mediated macrophage reprogramming and highlighting gaps in our understanding of the signaling mechanisms and clinical applications. We explore the signaling pathways and therapeutic potential of EVs in macrophage phenotyping, analyze e

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research